

## **REMARKS**

These remarks are in response to the Final Office Action mailed December 2, 2010. Applicants acknowledge the Examiner's statement that claims 1-7 and 11-14 are allowable. Claims 8, 9 and 16 have been amended. Support for the language in the amendment can be found throughout the specification as filed (see, e.g., paragraphs [00014]-[0016], [0032], and [0040], to name a few). No new matter is believed to have been introduced.

### **I. REJECTION UNDER 35 U.S.C. §112, FIRST PARAGRAPH**

Claim 8-10, 15, 16 and 18 stand rejected under 35 U.S.C. §112, first paragraph as allegedly failing to comply with the enablement requirement. Applicants respectfully traverse this rejection.

The Examiner has set forth the "Wands Factors" as a basis for the enablement rejection. Applicants respectfully submit that the literature (including issued patents, see, e.g., U.S. Pat. 6,602,849 of record in the present application) describe the use of somatostatin analogs linked to, for example, cytotoxic molecules and radio-nuclides for the treatment of helicobacter pylori infections and cancers (see, also, Sun and Coy, "Somatostatin receptor-targeted anti-cancer therapy," *Curr Drug Deliv.* 2011 Jan 1;8(1):2-10); Bal CS, Gupta SK, Zaknun JJ., *Trop Gastroenterol.* 2010 Apr-Jun;31(2):87-95. Review)).

The test of enablement is whether one skilled in the art could make or use the claimed invention from the disclosures in the patent ***coupled with information known in the art*** without undue experimentation. *United States v. Telectronics, Inc.*, 857 F.2d 778, 8 USPQ2d 1217 (Fed. Cir. 1988); *In re Stephens*, 529 F.2d 1343, 188 USPQ 659 (CCPA 1976); MPEP §2164.01 (emphasis ours). Information available in the art included assays useful for determining binding to various somatostatin receptors, receptor expression profiles on various cancer cells and pre-clinical and clinical experiments using somatostatin analogs to target and visualize cancer cells.

For example, Appendix A is an article by L. Kvols, one of the world's leading authorities in peptide therapy, showing the anti-proliferative effects of modified cyclic somatostatin analogs similar to those of the present invention in the treatment of neuroendocrine cancers. Furthermore, the claims are not directed to treating any

cancer or condition but rather those that express an SST receptor and which bind an analog of the disclosure. For at least the foregoing reasons, Applicants submit that the claimed invention is enabled with reference to the specification coupled with the knowledge available to those of skill in the art.

Claims 17 and 19 stand rejected under 35 U.S.C. §112, first paragraph as allegedly failing to comply with the enablement requirement. Applicants respectfully traverse this rejection.

As mentioned above, somatostatin analogs have been demonstrated to have an effect of *Helicobacter pylori* proliferation. Thus, the fact that minor experimentation (e.g., incubating an analog of the disclosure with *Helicobacter pylori*) using methods known in the art as described in WO/1999/056769, may be needed does not negate enablement, particularly where the experimentation is not undue (as is the case here). Accordingly, Applicants respectfully request withdrawal of the rejection.

## **II. REJECTION UNDER 35 U.S.C. §112, SECOND PARAGRAPH**

Claims 9, 10 and 15 stand rejected under 35 U.S.C. §112, second paragraph as allegedly being indefinite. Applicants respectfully traverse this rejection.

Claim 9 is allegedly unclear with respect to "what cell proliferative disorders" are being referred to in the claim. Applicants respectfully submit that the claim has been amended to recite a cell proliferative disorder having cells expressing an SST. Applicants believe this amendment address the rejection.

Claim 10 is allegedly indefinite for reciting an improper Markush group. Applicants have amended the claim and believe the amendment address the rejection.

Claim 15 is allegedly unclear because the type of effect on the receptor is unclear. Applicants have amended claim 15 and believe the amendment address the rejection.

For at least the foregoing, the Applicant submits that the claimed invention is patentable and request reconsideration and notice of such allowable subject matter.

The Director is authorized to charge any required fee or credit any overpayment to Deposit Account Number 50-4586, please reference the attorney docket number above.

The Examiner is invited to contact the undersigned at the below-listed telephone number, if it is believed that prosecution of this application may be assisted thereby.

Respectfully submitted,

GAVRILOVICH, DODD & LINDSEY LLP

Date: February 2, 2011

By: /Joseph R. Baker, Jr./  
Joseph R. Baker, Jr.  
Registration No. 40900

4660 La Jolla Village Drive, Suite 750  
San Diego, California 92122  
(858) 458-3607 (Main)  
(858) 458-9986 (Fax)

## **APPENDIX A**

## Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors

Jonathan Strosberg, Larry Kvols

Jonathan Strosberg, Larry Kvols, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States  
Author contributions: Strosberg J wrote this article and Kvols L reviewed it.

Correspondence to: Jonathan Strosberg, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States. [jonathan.strosberg@moffitt.org](mailto:jonathan.strosberg@moffitt.org)

Telephone: +1-813-7457257 Fax: +1-813-7457229

Received: February 23, 2010 Revised: March 24, 2010

Accepted: March 31, 2010

Published online: June 28, 2010

**Key words:** Somatostatin analogues; Neuroendocrine tumors; Antiproliferative

**Peer reviewer:** Loes van Keimpema, MSc, Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. *World J Gastroenterol* 2010; 16(24): 2963-2970 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v16/i24/2963.htm> DOI: <http://dx.doi.org/10.3748/wjg.v16.i24.2963>

### Abstract

Somatostatin analogs were initially developed for the control of hormonal syndromes associated with neuroendocrine tumors (NETs). In recent years, accumulating data has supported their role as antiproliferative agents, capable of stabilizing tumor growth in patients with metastatic neuroendocrine malignancies, including carcinoid and pancreatic endocrine tumors. A phase III, randomized, placebo-controlled trial has now demonstrated that octreotide long-acting repeatable (LAR) 30 mg can significantly prolong time to tumor progression among patients with metastatic midgut NETs regardless of functional status, chromogranin A level or age. In addition to significantly lengthening time to tumor progression in the overall study population, subset analysis suggests that patients with low tumor burden are most likely to experience disease stabilization with octreotide LAR 30 mg, supporting the early use of octreotide LAR in patients with metastatic disease. Further research efforts are underway to evaluate the use of somatostatin analogs as antiproliferative agents in other types of gastroenteropancreatic-NETs. Ongoing studies are also evaluating novel somatostatin analogs and somatostatin analogs in combination with other anti-tumor therapies.

© 2010 Baishideng. All rights reserved.

### INTRODUCTION

The human hormone somatostatin was first isolated in 1973 and identified as a hypothalamic inhibitor of growth hormone<sup>[1-4]</sup>. It was subsequently discovered in multiple tissues, including the central nervous system, endocrine system and gastrointestinal tract<sup>[5]</sup>. Somatostatin has been characterized as a universal endocrine “off-switch” due to its exocrine, endocrine, paracrine and autocrine inhibitory effects<sup>[5-7]</sup>. In the digestive tract, it reduces secretion and motility, decreases portal blood flow, inhibits gallbladder contraction and reduces the secretion of other gastrointestinal hormones<sup>[8]</sup>. The effects of somatostatin are mediated through interaction with five somatostatin receptors (sst1-5)<sup>[9]</sup>, belonging to a family of G-protein coupled receptors with seven transmembrane domains.

The clinical utility of native human somatostatin is limited by its short half life of approximately two minutes. Both bioactive forms of the hormone, the fourteen-peptide somatostatin-14 and a C-terminally extended form, somatostatin-28, contain multiple enzymatic cleavage sites resulting in rapid circulatory degradation<sup>[6]</sup>. In order to improve the pharmacokinetic profile, synthetic somatostatin

analogs (SSAs) have been developed by shortening the polypeptide chain while retaining binding affinity to somatostatin receptors (Figure 1)<sup>[10]</sup>. The two commercially available analogs, octreotide and lanreotide, are octapeptides that bind with high affinity to somatostatin receptor subtype 2 (sst<sub>2</sub>) and with moderate affinity to ssts (Table 1).

Octreotide has been used in clinical practice since data emerged in the 1980s confirming its ability to palliate carcinoid syndrome<sup>[14]</sup>, as well as other hormonal syndromes caused by metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Octreotide was initially available in an immediate-release formulation suitable for deep subcutaneous or intravenous administration<sup>[15]</sup>. Octreotide subcutaneous (sc) has been tested primarily at doses ranging from 100 to 500 µg two to three times daily. During the past decade, a long-acting repeatable (LAR) depot formulation of octreotide (Sandostatin LAR<sup>®</sup>) has been available, which allows monthly intramuscular dosing. Octreotide LAR has demonstrated similar efficacy to octreotide sc in the control of flushing and diarrhea associated with carcinoid syndrome<sup>[16]</sup>. The dose of octreotide sc and octreotide LAR should be titrated per symptom control for optimal patient care<sup>[17]</sup>. A second somatostatin analog, lanreotide, was licensed in Europe in 1998 for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors. A long-acting formulation of lanreotide (Somatuline Autogel<sup>®</sup>)<sup>[18]</sup> has also been developed as a deep subcutaneous injection.

Early on, clinical trials of SSAs tested their ability to inhibit the release of neuroendocrine hormones such as serotonin, glucagon, insulin, gastrin and vasoactive intestinal peptide (VIP)<sup>[14,19-22]</sup>. These trials formed the basis for the approval of octreotide and lanreotide as antisecretory agents indicated for treatment of hormonally active GEP-NETs. It was not until several years after the approval of octreotide that evidence of antineoplastic activity emerged. Although objective radiographic responses associated with SSAs were rare, many cases of prolonged disease stability were documented in the literature, leading to the hypothesis that SSAs exert an inhibitory effect on tumor growth. Recently, this hypothesis was tested in a Phase III, randomized, placebo-controlled clinical trial evaluating octreotide LAR 30 mg. This review summarizes the preclinical and clinical evidence supporting the role of SSAs as antiproliferative agents in the treatment of patients with GEP-NETs. To date, most data (including the results from the only phase III randomized, placebo-controlled trial) have been generated in studies evaluating octreotide sc and LAR.

## BIOLOGICAL BASIS FOR THE ANTIPROLIFERATIVE EFFECTS OF SSAS

Over the past two decades there has been significant progress in our understanding of the molecular basis for the antiproliferative effects of somatostatin and its analogs. Antitumoral activity appears to be mediated *via* direct and indirect mechanisms. Direct mechanisms involve the




Figure 1 Chemical structure of the synthetic somatostatin analogs octreotide and lanreotide (adapted from<sup>[10]</sup>).

Table 1 Receptor binding affinities of somatostatin, octreotide and lanreotide

	sst <sub>1</sub>	sst <sub>2</sub>	sst <sub>3</sub>	sst <sub>4</sub>	sst <sub>5</sub>
Receptor binding affinity (IC <sub>50</sub> nmol/L)					
Somatostatin <sup>[12]</sup>	0.93	0.15	0.56	1.50	0.29
Octreotide <sup>[12]</sup>	280.00	0.38	7.10	> 1000	6.30
Lanreotide <sup>[13]</sup>	> 1000	0.80	107	> 1000	5.20

Table 2 Receptor mediation of cell proliferation

	sst <sub>1</sub>	sst <sub>2</sub>	sst <sub>3</sub>	sst <sub>4</sub>	sst <sub>5</sub>
Induction of G1 cell cycle arrest	+	+		+	+
Induction of apoptosis		+	+		

activation of somatostatin receptors on tumor cells leading to modulation of intracellular signaling transduction pathways. Multiple *in vitro* studies using cell lines transfected with somatostatin receptors indicate that all receptor subtypes (sst<sub>1-5</sub>) may mediate inhibition of cell proliferation<sup>[23]</sup>, whereas specific receptor subtypes (sst<sub>2,3</sub>) may mediate apoptosis (Table 2)<sup>[24-26]</sup>. These actions appear to be regulated primarily *via* the MAP-kinase signaling pathway and through activation of phosphotyrosine phosphatases (Figure 2)<sup>[27-29]</sup>. Indirect antiproliferative mechanisms include inhibition of mitogenic growth factors such as insulin-like growth factor (IGF), as well as inhibition of tumor angiogenesis through interaction with somatostatin receptors on endothelial cells and monocytes<sup>[30]</sup>.

### Activation of phosphotyrosine phosphatases

Several phosphotyrosine phosphatases (PTPs), including SHP-1 and SHP-2, have emerged as important regulators of intracellular signaling pathways<sup>[27]</sup>. Somatostatin receptor-mediated activation of SHP-1 results in arrest of cell proliferation in various cell lines, including cells derived from pancreatic, breast and prostate carcinomas<sup>[31,32]</sup>. In pituitary adenoma cells, activation of sst<sub>2</sub> inhibits PI3 kinase activity and causes cell growth arrest *via* stimulation of SHP-1<sup>[33]</sup>. The enzymatic activity of SHP-1 has also been implicated in sst<sub>3</sub>-dependent apoptosis in transfected Chinese Hamster Ovary (CHO) cells<sup>[34]</sup>. Stimulation of SHP-1 in sst<sub>2</sub>-expressing CHO cells has led to G1 cell cycle arrest *via* induction of the cyclin-dependent kinase inhibitor p27<sup>[35]</sup>. SHP-2 has also been identified as a mediator of the antiproliferative effects of somatostatin receptors,




Figure 2 Somatostatin receptor-mediated effects on neuroendocrine cells (adapted from<sup>[28]</sup>).

primarily through inactivation of tyrosine kinase receptors for insulin and epidermal growth factors<sup>[36]</sup>. Moreover, activation of PTPs has been shown to down-regulate Raf-1<sup>[37]</sup> and block the MAP-kinase pathway<sup>[38]</sup>.

#### Modulation of the mitogen activated protein-kinase pathway

Both inhibition and stimulation of the mitogen activated protein (MAP)-kinase pathway have been linked to the antiproliferative effects of somatostatin and its analogs. In a glioma cell line, the receptor-like PTP, PTPeta, mediated the antiproliferative effects of somatostatin through inhibition of ERK1/2<sup>[39]</sup>. Conversely, another study of sst<sub>i</sub>-expressing CHO cells demonstrated that somatostatin robustly activated MAP-kinase, which in turn enhanced the expression of the cyclin-dependent kinase inhibitor p21, thereby inhibiting cell proliferation<sup>[40]</sup>. Another study in CHO cells demonstrated that activation of p38 MAP-kinase *via* sst<sub>2</sub> and sst<sub>4</sub> mediated the inhibitory effects of somatostatin on fibroblast growth factor induced proliferation<sup>[41]</sup>.

#### Indirect antiproliferative mechanisms

Suppression of tumor growth may occur *via* inhibition of various circulating growth factors, including insulin-like growth factor (IGF), epidermal growth factor (EGF) and growth hormone (GH). Inhibition of GH is thought to be mediated primarily *via* sst<sub>2</sub> and sst<sub>4</sub>, which are strongly expressed in the anterior pituitary<sup>[42-44]</sup>. Octreotide has been shown to suppress circulating levels of IGF-1, both

*via* suppression of pituitary secretion of GH as well as through direct inhibition of IGF-1 production in the liver<sup>[45,46]</sup>.

The antiangiogenic effects of octreotide have been demonstrated in multiple *in vitro* tumor models<sup>[47,48]</sup>. Octreotide has been shown to inhibit proliferating endothelial cells that over-express sst<sub>2</sub> and sst<sub>4</sub><sup>[49]</sup>. The primary mechanism of angiogenesis inhibition may be suppression of endothelial nitric oxide release<sup>[50]</sup>. Inhibition of circulating vascular-endothelial growth factor (VEGF) appears to also play a role in suppression of peritumoral vessel growth<sup>[51,52]</sup>.

### EARLY CLINICAL EVIDENCE FOR THE ANTIPROLIFERATIVE EFFECTS OF SSAs

Since the introduction of SSAs, multiple phase II trials and retrospective series have demonstrated that SSA treatment is associated with prolonged survival and disease stabilization in a large proportion of patients. For example, a single-institution retrospective study of 146 patients with metastatic mid-gut NETs, 91% of whom received long term octreotide treatment, demonstrated a 5-year survival rate of 75% (compared to 19% historically)<sup>[53]</sup>. Additionally, an analysis of the US-based Surveillance, Epidemiology and End Results (SEER) database found a significant increase in survival from 1988 to 2004 compared with 1973 to 1987, coinciding with the introduction of octreotide<sup>[54]</sup>.

In general, early clinical studies evaluating the dis-

ease-stabilizing effect of SSAs in patients with GEP-NETs are characterized by their lack of randomized design and enrollment of heterogeneous populations of patients with GEP-NETs. Although objective radiographic response rates have been rare (generally < 5%), the rate of tumor stabilization observed in most studies has ranged from 40%–60%, with higher rates observed in patients without documented disease progression at onset of treatment<sup>[55]</sup>.

Among the first prospective studies documenting the antiproliferative effects of SSAs in GEP-NETs was one conducted by the German Sandostatin Study Group<sup>[56]</sup>. In this study, 103 patients with metastatic carcinoid and pancreatic endocrine tumors were treated with octreotide 200 µg thrice daily until evidence of radiographic progression. Among patients who had disease progression documented at treatment outset, the rate of disease stability lasting at least 3 mo was 37%, whereas among patients with documented stable disease at treatment outset, disease stability lasting at least 12 mo was documented in 54% of patients<sup>[57]</sup>. No objective tumor responses were observed. Another phase II clinical trial testing octreotide as an antiproliferative agent in 34 patients with progressive metastatic NETs demonstrated a disease stabilization rate of 50% lasting a median of 5 mo<sup>[58]</sup>.

The antiproliferative effect of intramuscular lanreotide SR 30 mg every 10 or 14 d was evaluated in a phase II trial of 46 patients with carcinoid and pancreatic endocrine tumors. Two patients (4%) achieved an objective radiographic response while 19 patients (41%) experienced stable disease for a mean duration of 9.5 mo<sup>[59]</sup>. In another phase II study of lanreotide SR 30 mg in 55 patients with GEP-NETs (48 with carcinoid tumors, six with gastrinomas and one with a VIPoma), 7% of 31 assessable patients achieved a partial response and 81% experienced disease stability<sup>[60]</sup>. In one study of patients with progressive tumors, participants received either octreotide LAR 30 mg or lanreotide SR 60 mg (this study considered all patients as a single cohort). Among 31 assessable patients, 14 (45%) achieved disease stability *vs* 55% who continued to progress radiographically<sup>[61]</sup>. Overall survival was considerably prolonged among patients with stable *vs* progressive disease. In multivariate analysis, pancreatic endocrine tumors appeared significantly less likely to achieve disease stabilization compared to intestinal carcinoid tumors. Extra-hepatic metastases were also associated with a poor prognosis. Table 3 summarizes the results of multiple non-randomized clinical trials evaluating the antineoplastic effects of octreotide and lanreotide in GEP-NETs.

## THE PROMID TRIAL

Although providing initial evidence for the antitumor effects of SSAs, studies described in the previous section have a number of features that prevent them from providing conclusive evidence. Examples of these features include relatively small patient cohorts, lack of a randomized placebo control group, and analysis of heterogeneous populations. As such, to prove or to disprove an antiproliferative effect of octreotide LAR 30 mg, the PROMID

Table 3 Summary of non-randomized clinical trials evaluating the antiproliferative effect of somatostatin analogs *n* (%)

Analog	Author	<i>n</i>	CR/PR	SD	PD
Patients with documented tumor progression					
Lanreotide	Faiss <i>et al</i> <sup>[62]</sup> , 2003	22	1 (4)	7 (32)	14 (64)
Lanreotide	Aparicio <i>et al</i> <sup>[63]</sup> , 2001	35	1 (3)	20 (57)	14 (40)
Octreotide	Arnold <i>et al</i> <sup>[64]</sup> , 1993	52	0 (0)	19 (36)	33 (63)
Octreotide	Saltz <i>et al</i> <sup>[58]</sup> , 1993	34	0 (0)	17 (50)	17 (50)
Octreotide	di Bartolomeo <i>et al</i> <sup>[19]</sup> , 1996	58	2 (3)	27 (46)	29 (50)
		201	4 (1)	90 (45)	107 (53)
Patients without documented tumor progression					
Lanreotide	Wymenga <i>et al</i> <sup>[60]</sup> , 1999	31	2 (6)	25 (80)	4 (13)
Lanreotide	Ducieux <i>et al</i> <sup>[65]</sup> , 2000	39	2 (5)	21 (54)	16 (41)
Lanreotide	Eriksson <i>et al</i> <sup>[66]</sup> , 1997	19	1 (5)	12 (63)	6 (32)
Lanreotide	Tomasetti <i>et al</i> <sup>[66]</sup> , 1998	18	0 (0)	14 (77)	4 (22)
Octreotide	Tomasetti <i>et al</i> <sup>[66]</sup> , 2000	16	0 (0)	14 (87)	2 (12)
Octreotide	Ricci <i>et al</i> <sup>[68]</sup> , 2000	15	1 (6)	6 (40)	8 (53)
		138	6 (4)	92 (67)	40 (29)


CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

study was initiated. This randomized, double-blind, placebo-controlled, phase III trial, was among the very few randomized trials performed in patients with this rare tumor type. To avoid confounding variables, only patients with well-differentiated inoperable or metastatic midgut tumors were included. Additionally, octreotide LAR 30 mg was the only dose of octreotide LAR evaluated.

High-level evidence of the antiproliferative effects of octreotide emerged after publication of the PROMID trial<sup>[69]</sup>. Eighty-five participants with well-differentiated carcinoid tumors originating in the distal intestine and proximal colon were randomized to receive either octreotide LAR 30 mg or placebo until radiographic evidence of progression or death. The primary endpoint was time to tumor progression. Most patients (75%) had evidence of somatostatin receptor expression as evidenced by radio-tracer uptake on Octreoscan. Nearly half of patients (38%) manifested the carcinoid syndrome (flushing and/or diarrhea associated with elevation in urine 5-HIAA). Only patients with mild carcinoid syndrome who tolerated flushing without intervention or responded to treatment with loperamide and/or cholestyramine in cases of diarrhea were included.

Median time to tumor progression was 14.3 mo in the octreotide LAR 30 mg group *vs* 6.0 mo in the placebo group ( $P = 0.000072$ , Figure 3). This significantly lengthened time-to-tumor progression was seen in the overall study population, regardless of tumor functionality, chromogranin A level or age. At 6 mo, tumor progression was observed in 24% of patients on the octreotide LAR 30 mg arm *vs* 66% of patients receiving placebo ( $P = 0.0079$ ). Serious adverse events were nearly evenly balanced (11 patients in the octreotide LAR 30 mg arm and 10 patients in the placebo arm). On multivariate analysis, the highest rates of disease stabilization were observed in patients





**Figure 3** Kaplan Meier curve demonstrating time to tumor progression in patients treated with octreotide long-acting repeatable (LAR) vs placebo<sup>[80]</sup>. Log-rank test stratified by functional activity:  $P = 0.000072$ , HR = 0.34 (95% CI: 0.20-0.59).

with low hepatic tumor load (< 10%) and resected primary tumor, however both of these subgroups contained the majority of study patients. Even patients with higher hepatic tumor burden (> 10%) experienced a near doubling in time to progression on the octreotide LAR arm of the study. The small number of deaths in both treatment arms (seven in the octreotide LAR 30 mg arm; nine in the placebo arm) precluded any analysis of differences in survival.

## FUTURE DIRECTIONS

### Novel somatostatin analogs

NETs generally express multiple somatostatin receptors<sup>[13,70]</sup>, all of which may mediate the antiproliferative effects of SSAs. These receptor subtypes can undergo heterodimerization with each other and with other receptor families (such as the dopamine receptor family), enhancing their binding affinities and internalization<sup>[71,72]</sup>. Thus, novel SSAs that bind to multiple receptor subtypes as well as analogs capable of binding to different families of receptors may prove to be effective antisecretory and antiproliferative agents in patients refractory to octreotide or lanreotide.

Pasireotide is one such novel somatostatin analog; it binds avidly to four of the five somatostatin receptors (sst1,2,3 and sst5). Compared with octreotide, pasireotide has a 40-, 30- and 5-fold higher binding affinity for sst5, sst1 and sst3, and a slightly lower affinity for sst2<sup>[73]</sup>. Pasireotide also has a 2-times higher binding affinity for sst5 than endogenous somatostatin<sup>[73]</sup>. In an *in vitro* study evaluating the use of octreotide and pasireotide on HEK293 cells expressing somatostatin receptor subtype sst2 on the cell membrane, treatment with octreotide resulted in an internalization of sst2 receptors at 30 min whereas treatment with pasireotide did not lead to sst2 internalization. Such findings may suggest that a persistent and more durable efficacy could be obtained with pasireotide<sup>[74]</sup>.

An open-label trial evaluated the activity of pasireotide sc in patients with carcinoid syndrome whose symptoms

(flushing and diarrhea) were inadequately controlled with octreotide LAR<sup>[75]</sup>. Preliminary data indicated activity in this refractory population. Future clinical trials are being designed to test the antiproliferative effects of pasireotide in neuroendocrine carcinomas. Other compounds capable of interacting with sst2 as well as with the dopamine D2 receptor (DAD2) are in clinical development<sup>[76]</sup>.

Radioactive labeling of SSAs is another promising approach to treatment of neuroendocrine malignancies which express high levels of somatostatin receptors. Early clinical trials employing <sup>111</sup>In-pentetreotide produced limited objective responses, probably due to the small particle range and short tissue penetration of Auger electrons emitted by the <sup>111</sup>In isotope<sup>[77]</sup>. The next generation of radiolabeled SSAs used <sup>90</sup>Y-DOTATOC, a  $\beta$ -particle emitter with a tissue range of approximately 12 mm<sup>[78-80]</sup>. Objective response rates of 10%-30% were reported in phase I and II clinical trials. Dose-limiting side effects included bone marrow and renal toxicity.

The latest research efforts in radiolabeled SSAs have focused on <sup>177</sup>Lu octreotate, a  $\beta$ - and  $\gamma$ -emitting radionuclide with a shorter range of tissue penetration (2 mm) than <sup>90</sup>Y. A recent phase II clinical trial reported an objective radiographic response rate of 30% among 310 patients with GEP-NETs, and a median progression-free survival duration of 40 mo<sup>[81]</sup>.

## CONCLUSION

SSAs were initially developed as antisecretory agents used primarily for the control of hormonal syndromes associated with NETs. In recent years, accumulating laboratory and clinical data has supported their role as antiproliferative agents, capable of stabilizing tumor growth in a large proportion of patients with metastatic carcinoid and pancreatic endocrine tumors. The recently-published PROMID study provides high-level evidence validating the role of octreotide LAR 30 mg as an antiproliferative agent in patients with metastatic carcinoid tumors of the midgut. Subset analysis suggests that patients with low tumor burden are most likely to experience disease stabilization, supporting the early use of octreotide LAR 30 mg in patients with metastatic disease. Further research efforts are underway to evaluate the use of novel SSAs, SSAs as antiproliferative agents in other types of GEP-NETs, and SSAs in combination with other anti-tumor agents.

## REFERENCES

- 1 Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science* 1973; **179**: 77-79
- 2 Brazeau P, Guillemin R. Editorial: Somatostatin: newcomer from the hypothalamus. *N Engl J Med* 1974; **290**: 963-964
- 3 Reichlin S. Somatostatin. *N Engl J Med* 1983; **309**: 1495-1501
- 4 Reichlin S. Somatostatin (second of two parts). *N Engl J Med* 1983; **309**: 1556-1563
- 5 Evers BM, Parekh D, Townsend CM Jr, Thompson JC. Somatostatin and analogues in the treatment of cancer. A review.

- Ann Surg* 1991; **213**: 190-198
- 6 **Bousquet C**, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. *Chemotherapy* 2001; **47** Suppl 2: 30-39
- 7 **Weckbecker G**, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. *Pharmacol Ther* 1993; **60**: 245-264
- 8 **Lamberts SW**, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. *N Engl J Med* 1996; **334**: 246-254
- 9 **Maurer R**, Reubi JC. Somatostatin receptors. *JAMA* 1985; **253**: 2741
- 10 **Bauer W**, Briner U, Doepfner W, Haller R, Huguenin R, Marchach P, Petcher TJ, Pless. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. *Life Sci* 1982; **31**: 1133-1140
- 11 **Susini C**, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. *Ann Oncol* 2006; **17**: 1733-1742
- 12 **Bruns C**, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antiseecretory profile. *Eur J Endocrinol* 2002; **146**: 707-716
- 13 **Hofland LJ**, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. *Endocr Rev* 2003; **24**: 28-47
- 14 **Kvols LK**, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. *N Engl J Med* 1986; **315**: 663-666
- 15 Sandostatin® Injection [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2005
- 16 **Rubin J**, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. *J Clin Oncol* 1999; **17**: 600-606
- 17 **Oberg K**, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. *Ann Oncol* 2004; **15**: 966-973
- 18 **Ruszniewski P**, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. *Neuroendocrinology* 2004; **80**: 244-251
- 19 **di Bartolomeo M**, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. *Cancer* 1996; **77**: 402-408
- 20 **Vezzosi D**, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-ss2A and anti-ss25 antibodies. *Eur J Endocrinol* 2005; **152**: 757-767
- 21 **O'Dorisio TM**, Gaginella TS, Mekhjian HS, Rao B, O'Dorisio MS. Somatostatin and analogues in the treatment of VIPoma. *Ann N Y Acad Sci* 1988; **527**: 528-535
- 22 **Boden G**, Ryan IG, Eischenschmid BL, Shelmet JJ, Owen OE. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. *N Engl J Med* 1986; **314**: 1686-1689
- 23 **Weckbecker G**, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. *Nat Rev Drug Discov* 2003; **2**: 999-1017
- 24 **Sharma K**, Srikant CB. G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification. *Biochem Biophys Res Commun* 1998; **242**: 134-140
- 25 **Sharma K**, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. *Int J Cancer* 1998; **76**: 259-266
- 26 **Lattuada D**, Casnici C, Venuto A, Marelli O. The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes. *J Neuroimmunol* 2002; **133**: 211-216
- 27 **Florio T**. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. *Mol Cell Endocrinol* 2008; **286**: 40-48
- 28 **Florio T**, Thellung S, Arena S, Corsaro A, Bajetto A, Schettini G, Stork PJ. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. *J Physiol Paris* 2000; **94**: 239-250
- 29 **Barbieri F**, Pattarozzi A, Gatti M, Aiello C, Quintero A, Lunardi G, Bajetto A, Ferrari A, Culler MD, Florio T. Differential efficacy of SSTR1, 2 and 5 agonists in the inhibition of C6 glioma growth in nude mice. *Am J Physiol Endocrinol Metab* 2009; Epub ahead of print
- 30 **Florio T**, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. *Endocrinology* 2003; **144**: 1574-1584
- 31 **Zapata PD**, Roperio RM, Valencia AM, Buscail L, López JL, Martín-Orozco RM, Prieto JC, Angulo J, Susini C, López-Ruiz P, Colás B. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. *J Clin Endocrinol Metab* 2002; **87**: 915-926
- 32 **Thangaraju M**, Sharma K, Liu D, Shen SH, Srikant CB. Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. *Cancer Res* 1999; **59**: 1649-1654
- 33 **Theodoropoulou M**, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U, Stalla GK. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zacl expression. *Cancer Res* 2006; **66**: 1576-1582
- 34 **Sharma K**, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. *Mol Endocrinol* 1996; **10**: 1688-1696
- 35 **Pagès P**, Benali N, Saint-Laurent N, Estève JP, Schally AV, Tkaczuk J, Vaysse N, Susini C, Buscail L. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. *J Biol Chem* 1999; **274**: 15186-15193
- 36 **Held-Feindt J**, Forstreuter F, Pufe T, Mentlein R. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. *Brain Res Mol Brain Res* 2001; **87**: 12-21
- 37 **Dent P**, Wang Y, Gu YZ, Wood SL, Reardon DB, Mangues R, Pellicer A, Schonbrunn A, Sturgill TW. S49 cells endogenously express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ. *Cell Signal* 1997; **9**: 539-549
- 38 **Reardon DB**, Dent P, Wood SL, Kong T, Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. *Mol Endocrinol* 1997; **11**: 1062-1069

- 39 **Massa A**, Barbieri F, Aiello C, Iuliano R, Arena S, Pattarozzi A, Corsaro A, Villa V, Fusco A, Zona G, Spaziante R, Schettini G, Florio T. The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2. *Ann N Y Acad Sci* 2004; **1030**: 264-274
- 40 **Florio T**, Yao H, Carey KD, Dillon TJ, Stork PJ. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). *Mol Endocrinol* 1999; **13**: 24-37
- 41 **Alderton F**, Humphrey PP, Sellers LA. High-intensity p38 kinase activity is critical for p21(cip1) induction and the anti-proliferative function of G(i) protein-coupled receptors. *Mol Pharmacol* 2001; **59**: 1119-1128
- 42 **Koch BD**, Schonbrunn A. The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes. *Endocrinology* 1984; **114**: 1784-1790
- 43 **Schonbrunn A**, Dorfinger LJ, Koch BD. Mechanisms of somatostatin action in pituitary cells. *Adv Exp Med Biol* 1985; **188**: 305-324
- 44 **Schettini G**, Florio T, Meucci O, Landolfi E, Lombardi G, Marino A. Somatostatin inhibition of anterior pituitary adenylate cyclase activity: different sensitivity between male and female rats. *Brain Res* 1988; **439**: 322-329
- 45 **Ambler GR**, Butler AA, Padmanabhan J, Breier BH, Gluckman PD. The effects of octreotide on GH receptor and IGF-I expression in the GH-deficient rat. *J Endocrinol* 1996; **149**: 223-231
- 46 **Serri O**, Brazeau P, Kachra Z, Posner B. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action. *Endocrinology* 1992; **130**: 1816-1821
- 47 **Woltering EA**, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. *Invest New Drugs* 1997; **15**: 77-86
- 48 **Danesi R**, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). *Clin Cancer Res* 1997; **3**: 265-272
- 49 **Adams RL**, Adams IP, Lindow SW, Zhong W, Atkin SL. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. *Br J Cancer* 2005; **92**: 1493-1498
- 50 **Arena S**, Pattarozzi A, Corsaro A, Schettini G, Florio T. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. *Mol Endocrinol* 2005; **19**: 255-267
- 51 **Kumar M**, Liu ZR, Thapa L, Qin RY. Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts. *Carcinogenesis* 2004; **25**: 2075-2081
- 52 **Kumar M**, Liu ZR, Thapa L, Chang Q, Wang DY, Qin RY. Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. *World J Gastroenterol* 2004; **10**: 393-399
- 53 **Strosberg J**, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. *Neuroendocrinology* 2009; **89**: 471-476
- 54 **Yao JC**, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol* 2008; **26**: 3063-3072
- 55 **Plöckinger U**, Wiedenmann B. Treatment of gastroenteropancreatic neuroendocrine tumors. *Virchows Arch* 2007; **451** Suppl 1: S71-S80
- 56 **Arnold R**, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumors: effect of Sandostatin on tumor growth. The German Sandostatin Study Group. *Metabolism* 1992; **41**: 116-118
- 57 **Arnold R**, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. *Gut* 1996; **38**: 430-438
- 58 **Saltz L**, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, Kelsen D. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. *Cancer* 1993; **72**: 244-248
- 59 **Ducreux M**, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. *Am J Gastroenterol* 2000; **95**: 3276-3281
- 60 **Wymenga AN**, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Välimäki MJ, Renstrup J, de Vries EG, Oberg KE. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. *J Clin Oncol* 1999; **17**: 1111
- 61 **Panzuto F**, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pedersoli P, Delle Fave G. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. *Endocr Relat Cancer* 2005; **12**: 1083-1092
- 62 **Faiss S**, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. *J Clin Oncol* 2003; **21**: 2689-2696
- 63 **Aparicio T**, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. *Eur J Cancer* 2001; **37**: 1014-1019
- 64 **Arnold R**, Neuhaus C, Benning R, Schwerek WB, Trautmann ME, Joseph K, Bruns C. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. *World J Surg* 1993; **17**: 511-519
- 65 **Eriksson B**, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. *Ann Oncol* 1997; **8**: 1041-1044
- 66 **Tomassetti P**, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. *Am J Gastroenterol* 1998; **93**: 1468-1471
- 67 **Tomassetti P**, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. *Aliment Pharmacol Ther* 2000; **14**: 557-560
- 68 **Ricci S**, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. *Ann Oncol* 2000; **11**: 1127-1130
- 69 **Rinke A**, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol* 2009; **27**: 4656-4663
- 70 **Nasir A**, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, Kelley ST, Centeno BA, Coppola D, Malafa ME, Yeatman TJ, Kvols LK. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. *Cancer Control* 2006; **13**: 52-60
- 71 **Rocheville M**, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. *Science* 2000; **288**: 154-157

- 72 **Rocheville M**, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. *J Biol Chem* 2000; **275**: 7862-7869
- 73 **Schmid HA**. Pasireotide (SOM230): development, mechanism of action and potential applications. *Mol Cell Endocrinol* 2008; **286**: 69-74
- 74 **Van Vugt HH**, Schmid HA, Sailer AW. Ligand-dependent internalization of somatostatin receptors. *Endocrine Abstracts* 2008; **16**: P659
- 75 **Kvols L**, Wiedenmann B, Oberg K, Glusman J, O'Dorisio T, de Herder WW, Gao B, Arnold R, Anthony L, The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. ASCO GI Cancers Symposium 2006; abst 171
- 76 **Jaquet P**, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. *Eur J Endocrinol* 2005; **153**: 135-141
- 77 **Valkema R**, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, de Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. *Semin Nucl Med* 2002; **32**: 110-122
- 78 **Valkema R**, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. *Semin Nucl Med* 2006; **36**: 147-156
- 79 **Waldherr C**, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90Y)-DOTATOC. *J Nucl Med* 2002; **43**: 610-616
- 80 **Paganelli G**, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Mäcke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. *Eur J Nucl Med* 2001; **28**: 426-434
- 81 **Kwekkeboom DJ**, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol* 2008; **26**: 2124-2130

S-Editor Wang YR L-Editor O'Neill M E-Editor Wu PZ